MEDCL.PA Stock - MedinCell S.A.
Unlock GoAI Insights for MEDCL.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $25.54M | $9.16M | $9.94M | $4.09M | $8.19M |
| Gross Profit | $25.54M | $9.16M | $9.94M | $4.09M | $6.74M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 82.3% |
| Operating Income | $-10,840,000 | $-20,977,000 | $-24,025,000 | $-23,814,000 | $-15,607,000 |
| Net Income | $-18,438,000 | $-25,038,000 | $-32,010,000 | $-24,806,000 | $-19,020,000 |
| Net Margin | -72.2% | -273.3% | -321.9% | -606.5% | -232.3% |
| EPS | $-0.63 | $-0.88 | $-1.27 | $-1.00 | $-0.86 |
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
Visit WebsiteEarnings History & Surprises
MEDCL.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 9, 2025 | $-0.26 | $-0.49 | -88.5% | ✗ MISS |
Q2 2025 | Jun 17, 2025 | $-0.42 | $-0.12 | +71.4% | ✓ BEAT |
Q4 2024 | Dec 3, 2024 | — | $-0.50 | — | — |
Q2 2024 | Jun 25, 2024 | — | $-0.58 | — | — |
Q4 2023 | Dec 21, 2023 | — | $-0.29 | — | — |
Q2 2023 | Jun 27, 2023 | — | $-0.72 | — | — |
Q4 2022 | Dec 6, 2022 | — | $-0.55 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.52 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.47 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.33 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.50 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.74 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.45 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.49 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.68 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.33 | — | — |
Q3 2017 | Sep 30, 2017 | — | $-0.34 | — | — |
Latest News
Frequently Asked Questions about MEDCL.PA
What is MEDCL.PA's current stock price?
What is the analyst price target for MEDCL.PA?
What sector is MedinCell S.A. in?
What is MEDCL.PA's market cap?
Does MEDCL.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MEDCL.PA for comparison